Hyperbilirubinemia, augmentation of endothelial function, and decrease in Oxidative stress in gilbert syndrome

Circulation

Volumn 126, Issue 5, 2012, Pages 598-603

  Maruhashi, Tatsuya ^a   Soga, Junko ^a   Fujimura, Noritaka ^a   Idei, Naomi ^a   Mikami, Shinsuke ^a   Iwamoto, Yumiko ^a   Kajikawa, Masato ^a   Matsumoto, Takeshi ^a   Kihara, Yasuki ^a   Chayama, Kazuaki ^a   Noma, Kensuke ^b   Nakashima, Ayumu ^c   Tomiyama, Hirofumi ^d   Takase, Bonpei ^e   Yamashina, Akira ^d   Higashi, Yukihito ^b,c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

bilirubin; endothelial function; Gilbert syndrome; oxidative stress; peripheral vascular diseases

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BILIRUBIN; CREATININE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD VESSEL FUNCTION; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENDOTHELIAL FUNCTION; GILBERT DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; URINARY EXCRETION; VASODILATATION;

ADULT; BILIRUBIN; BRACHIAL ARTERY; CASE-CONTROL STUDIES; DEOXYGUANOSINE; ENDOTHELIUM, VASCULAR; GILBERT DISEASE; HUMANS; HYPERBILIRUBINEMIA; LIPOPROTEINS, LDL; MALE; NITROGLYCERIN; OXIDATIVE STRESS; REGIONAL BLOOD FLOW; VASODILATION;

EID: 84864473444     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.105775     Document Type: Article

References (37)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Leopold JA, Loscalzo J. Oxidative enzymopathies and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1332-1340.
3. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008;5:338-349. (Pubitemid 351761708)
4. Drexler H, Horning B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999;31:51-60. (Pubitemid 29078218)
5. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678. (Pubitemid 33108132)
6. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. 2002;346:1954-1962. (Pubitemid 34651355)
7. Gilbert A, Lereboullet P. La cholémie simple familiale. Semaine Med. 1901;21:241-243.
8. Owens D, Evans J. Population studies on Gilbert's syndrome. J Med Genet. 1975;12:152-156.
9. Sieg A, Arab L, Schlierf G, Stiehl A, Kommerell B. Prevalence of Gilbert's syndrome in Germany. Dtsch Med Wochenschr. 1987;112: 1206-1208.
10. Kapitulnik J. Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol. 2004;66: 773-779. (Pubitemid 39319447)
11. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235:1043-1046. (Pubitemid 17049750)
12. Doré S, Takahashi M, Ferris CD, Zakhary R, Hester LD, Guastella D, Snyder SH. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc Natl Acad Sci USA. 1999;96:2445-2450. (Pubitemid 29117935)
13. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ, Motterlini R. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol. 2000;278:H643-H651. (Pubitemid 30131266)
14. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008;60:79-127. (Pubitemid 351439218)
15. Inoguchi T, Sasaki S, Kobayashi K, Takayanagi R, Yamada T. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA. 2007;298:1398-1400. (Pubitemid 47481621)
16. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP, Chowdhury NR. The genetic basis of the reduced expression of bilirubin UDPglucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995; 333:1171-1175.
17. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, Kronenberg F. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006;114:476-1481.
18. V́tek L, Jirsa M, Brodanová M, Kalab M, Marecek Z, Danzig V, Novotný L, Kotal P. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002;160: 449-456. (Pubitemid 34159340)
19. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97:2222-2229. (Pubitemid 28265383)
20. Dijhorst-Oei LT, Stores ES, Koomans HA, Rabelink TJ. Acute simultaneous stimulation of nitric oxide and oxygen radicals by angiotensin II in humans in vivo. J Cardiovasc Pharmacol. 1999;33:420-424. (Pubitemid 29101986)
21. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
22. Nakae D, Kobayashi Y, Akai H, Andoh N, Satoh H, Ohashi K, Tsutsumi M, Konishi Y. Involvement of 8-hydroxyguanine formation in the initial of rat river carcinogenesis by low dose levels of N-nitrosodiethylamine. Cancer Res. 1997;57:1281-1287. (Pubitemid 27152552)
23. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98: 1487-1494. (Pubitemid 28481664)
24. Miyazaki T, Shimada K, Sato O, Kotani K, Kume A, Sumiyoshi K, Sato Y, Ohmura H, Watanabe Y, Mokuno H, Daida H. Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease. Atherosclerosis. 2005;179:139-145. (Pubitemid 40249796)
25. Ryter SW, Choi AM. Heme oxygenase-1/carbon monoxide: from metabolism to molecular therapy. Am J Respir Cell Mol Biol. 2009;41:251-260.
26. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA. 2002;99: 16093-16098. (Pubitemid 35462754)
27. Romero JC, Reckelhoff JF. Role of angiotensin and oxidative stress in essential hypertension. Hypertension. 1999;34:943-949. (Pubitemid 29501328)
28. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest. 1996;97:1916-1923.
29. Kwak JY, Takeshige K, Cheung BS, Minakami S. Bilirubin inhibits the activation of superoxide-producing NADPH oxidase in a neutrophil cell-free system. Biochim Biophys Acta. 1991;1076:369-373.
30. Lanone S, Bloc S, Foresti R, Almolki A, Taillé C, Callebert J, Conti M, Goven D, Aubier M, Dureuil B, El-Benna J, Motterlini R, Boczkowski J. Bilirubin decreases NOS2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J. 2005;19:1890-1892. (Pubitemid 41598785)
31. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994;40:18-23. (Pubitemid 24050206)
32. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1996;16: 250-255. (Pubitemid 26056243)
33. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol. 2008;28:166-172.
34. Kawamura K, Ishikawa K, Wada Y, Kimura S, Matsumoto H, Kohro T, Itabe H, Kodama T, Maruyama Y. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol. 2005;25:155-160. (Pubitemid 40054269)
35. Croom KF, Dhillon S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009;69:1107-1140.
36. Dekker D, Dorresteijn MJ, Pijnenburg M, Heemskerk S, Rasing-Hoogveld A, Burger DM, Wagener FA, Smits P. The bilirubinincreasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2011; 31:458-463.
37. Dubé MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis. 2008;47:567-574.